Drugs for Depression and Anxiety Disorders
Selective Serotonin Reuptake Inhibitors
• Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone
• Anxiety and depression disorders
• Obsessive-compulsive disorder, PTSD
• SERT selective; little effect on NET
• Vilazodone also acts as 5HTIA partial agonist
Serotonin-Norepinephrine Reuptake Inhibitors
• Venlafaxine, Desvenlafaxine, Duloxetine, Milnacipran, Levomilnacipran
• Anxiety and depression, ADHD, autism, fibromyalgia, PTSD, menopause symptoms
• Inhibitors of SERT and NET
Tricyclic Antidepressants
Amitriptyline, Clomipramine, Doxepin, Imipramine, Trimipramine, Nortriptyline, Maprotiline, Protriptyline, Desipramine, Amoxapine
• Block SERT, NET, a1, H1 and M1 receptors
• Major depression
Atypical Antipsychotics
• Aripiprazole, Brexpiprazole, Lurasidone, Olanzapine, Quetiapine, Risperidone
• Resistant major depression and psychotic disorders
• Schizophrenia
• Bipolar depression
Monoamine Oxidase Inhibitors
• Isocarboxazid, Phenelzine, Selegiline, Tranylcypromine
• Inhibit MAOA and MAOB to prevent NE, DA, and 5HT breakdown
• Major depression disorders resistant to other antidepressants
Atypical Antidepressants
• Bupropion, Trazodone, Nefazodone, Mirtazapine, Mianserin, Vortioxetine
• Depression
• Smoking cessation (bupropion)
• Insomnia (low-dose trazodone)
#Depression #Anxiety #Disorders #Medications #Table #Pharmacology #Management
Heart Failure (HFrEF) Treatment - GDMT for stage C
For patients with Heart Failure with REDUCED Ejection Fraction (HFrEF), we follow Guideline-Directed Medical Therapy (GDMT). GDMT is basically getting patients on medication regimens that have been evidenced to have a mortality benefit, while also considering adding other agents for morbidity benefits when appropriate. In patients with HFrEF, we should initiate them on ACEI or ARB and an evidenced beta-blocker since these have mortality benefits. It's important to have both of these medications on board, then titrate them up to the target dose (as tolerated). If patients have edema then add on loop diuretics. After a patient is on maximally tolerated ACEI/ARB + Beta-Blocker, we can move to the next section of possible agents. Agents with mortality benefit in second-line include Entresto (replacing ACEI/ARB), spironolactone, and BiDil (for African American patients). Additionally we can consider adding ivabradine if patients HR is still >70 despite the beta blocker. This process is recommended by the ACC/AHA guidelines. We may also consider digoxin for morbidity benefits in certain situations as well.
Jarred Prudencio, PharmD - https://www.instagram.com/ambcarerx
#CHF #sCHF #HeartFailure #HFrEF #Pharmacology #Management #Treatment #StageC #Cardiology